Busulfan Injection, 60 mg recall — Sagent Pharmaceuticals (Class III)
Sagent Pharmaceuticals is recorded by the U.S. Food and Drug Administration (FDA) as recalling Busulfan Injection, 60 mg — a Class III recall, initiated 2026-05-04 and posted to the FDA enforcement report on 2026-05-27, under recall number D-0539-2026. Status Ongoing, with no termination date on the record. The reason the FDA record carries is, verbatim: “Failed Impurities/Degradation Specifications”. From the product description, the form is injection, the strengths given are 60 mg, 10 mL and 6 mg and it is marked Rx only. 1 National Drug Code number is printed in the record: 25021-241-10. Distribution is recorded as “Nationwide within the United States” — Nationwide (US), with the recalling firm on record in IL, United States. It is the only recall number the FDA has filed under event ID 98883. Values are reproduced from the linked openFDA report; regulatory information, not medical advice.
Regulatory snapshot
| Recall number | D-0539-2026 |
|---|---|
| FDA event ID | 98883 |
| Classification | Class III (least serious regulatory tier) |
| Status | Ongoing |
| Recalling firm | Sagent Pharmaceuticals |
| Recall initiated | 2026-05-04 |
| Reported by FDA | 2026-05-27 |
| Report lag | 23 days from initiation to report |
| Distribution | Nationwide within the United States — Nationwide (US) |
| Firm location on record | IL, United States |
| Product description (source) | Busulfan Injection, 60 mg per 10 mL (6 mg per mL), 8x10 mL Single-Dose Vials, Rx only, Mfd. for Sagent Pharmaceuticals, Schaumburg, IL 60195, Made in Canada, NDC 25021-241-10. |
Reason reported by FDA
Failed Impurities/Degradation Specifications
3 words from the enforcement report field reason_for_recall, reproduced without edit — the firm's own wording, not an assessment.
Product identifiers in this record
7 identifying values matched by exact pattern in the 29-word product description above; each is a literal substring of it.
| Product named | Busulfan Injection |
|---|---|
| Form | Injection |
| Strength | 60 mg · 10 mL · 6 mg |
| NDC | 25021-241-10 |
| Marketing category | Rx only |
| Stated origin | Canada |
Reported in the same month (2026-05)
48 enforcement reports carry a report date in 2026-05; these 8 are the Class III ones nearest this record.
| Recall record | Recall number | Recalling firm | FDA tier | Reported |
|---|---|---|---|---|
| Primidone Tablets USP, 250mg | D-0533-2026 | Lannett Company Inc. | Class III | 2026-05-27 |
| Primidone Tablets, 50 mg | D-0534-2026 | Golden State Medical Supply Inc. | Class III | 2026-05-27 |
| Primidone Tablets, 250 mg | D-0535-2026 | Golden State Medical Supply Inc. | Class III | 2026-05-27 |
| Primidone Tablets, 250 mg | D-0536-2026 | Amerisource Health Services LLC | Class III | 2026-05-27 |
| Primidone Tablets, 50 mg | D-0537-2026 | Amerisource Health Services LLC | Class III | 2026-05-27 |
| busPIRone Hydrochloride Tablets, 5 mg | D-0511-2026 | Unichem Pharmaceuticals Usa Inc. | Class III | 2026-05-13 |
| Levocarnitine Injection, 1 g/5 mL | D-0494-2026 | American Regent, Inc. | Class III | 2026-05-06 |
| Lidocaine Wound Gel, 0.13% | D-0509-2026 | Water-jel Technologies, LLC | Class III | 2026-05-06 |
Nearest Class III recalls by date
25 of 250 indexed records share the Class III tier; the 8 nearest to 2026-05-27 by report date are listed here.
| Recall record | Recall number | Recalling firm | Strength / form | Reported |
|---|---|---|---|---|
| Nicotine Transdermal System Patch, 14 mg | D-0550-2026 | Aveva Drug Delivery Systems, Inc. | 14 mg · Transdermal System | 2026-06-03 |
| PRED MILD, 0.12% | D-0551-2026 | Abbvie Inc. | 0.12% · Ophthalmic Suspension | 2026-06-03 |
| Lidocaine HCl Injection, 2% | D-0552-2026 | Eugia US LLC | 2% · Injection | 2026-06-10 |
| Epinephrine Injection, 1mg/mL | D-0581-2026 | Fresenius Kabi Usa, LLC | 1mg/mL · Injection | 2026-06-17 |
| Primidone Tablets, 50 mg | D-0585-2026 | Amneal Pharmaceuticals, LLC | 50 mg · Tablets | 2026-06-17 |
| Premier, 8 mL | D-0490-2026 | Premier Dental Products Co | 8 mL · Solution | 2026-04-29 |
| Focalin XR (dexmethylphenidate HCl) 5 mg | D-0608-2026 | Sandoz Inc | 5 mg · Extended-Release Capsules | 2026-06-24 |
| hydrOXYzine Hydrochloride Oral Solution, 10 mg/5 mL | D-0619-2026 | Ani Pharmaceuticals, Inc. | 10 mg/5 mL · Oral Solution | 2026-07-01 |
Reading this record
Class III is the FDA's own severity tier for the recall action — 25 of the 250 indexed records carry it — and it describes the agency's assessment of the action, not a risk statement about any individual. Match a package against 25021-241-10 at the FDA source to confirm it is covered.
Namespace context: the Class III index (25 records) and the recall hub (250 records, 118 FDA events); Sagent Pharmaceuticals (6 indexed records) aggregates this firm across datasets.
Coverage and limits of this record
This page reflects the openFDA enforcement report for D-0539-2026 as ingested on 2026-08-22, which can lag the live FDA record and omits detail held only in primary documents. It offers no clinical assessment, no advice about whether to use any product, and no substitute. For any health question consult a qualified healthcare professional.
Source & provenance
- Official source
- https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0539-2026%22
- Source dataset
- openFDA Drug Enforcement API
- Publication date
- 2026-05-27
- Ingested
- 2026-08-22
- Record hash
a158fa6d903fa98c
Verify every value against the official FDA source above. This site links to the regulator's record rather than replacing it.